{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:21:38Z","timestamp":1769574098211,"version":"3.49.0"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Biologics are effective for the treatment of psoriasis, but little is known regarding patients treated with one biologic for an \u2018ultra-long\u2019 duration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To explore the prevalence, patient and treatment characteristics, and treatment outcomes of ultra-long users of biologics for psoriasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data for patients with psoriasis who had received continuous treatment with the same biologic for \u2265 10\u2005years were collected from the prospective, multicentre BioCAPTURE cohort. Baseline characteristics of these ultra-long users were determined and compared with the total BioCAPTURE population. The proportion of patients using concomitant systemic treatment and receiving dose adjustments, the trajectory of Psoriasis Area and Severity Index scores and drug survival rates beyond 10\u2005years were also analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the BioCAPTURE cohort, 30.5% of patients with the potential to achieve a treatment episode of \u2265 10\u2005years reached this treatment duration. These patients were treated with ustekinumab, etanercept, adalimumab and infliximab. The proportion of ultra-long users was highest for ustekinumab (37.1%). The ultra-long user cohort had a slightly longer disease duration at registry entry, and a higher proportion of men and patients diagnosed with psoriatic arthritis (PsA) than the total BioCAPTURE population. Among the cohort, 69.5% of patients had at least one comorbidity and 66.1% used no additional systemic antipsoriatic treatment. Dose adjustments were often applied, varying from dose escalation (29.7%), dose reduction (40.7%) or both (13.6%); only 16.1% of patients consistently used the standard dose throughout their treatment. The median PASI score for ultra-long users from month 6 onwards was consistently &amp;lt; 3, with only a small proportion achieving complete clearance of their psoriasis (3.9\u201313.7% at the various timepoints). Drug survival analysis beyond 10\u2005years showed that 62.3% of patients were still being treated with the same biologic after 15\u2005years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ultra-long use of the same biologic in patients with psoriasis was common in real-world practice but varied between biologics. The median PASI score was around 2.5 throughout the 10-year treatment course; complete clearance was often not achieved. Remarkably, ultra-long use was also recorded in patients with multiple comorbidities (including PsA). Dose adjustments of the biologic were applied in the majority of patients. These results provide clinicians with important evidence on ultra-long treatment with biologics, thereby improving psoriasis care and the management of treatment expectations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae333","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T22:49:34Z","timestamp":1723589374000},"page":"348-356","source":"Crossref","is-referenced-by-count":1,"title":["Revealing patient characteristics and treatment outcomes among ultra-long users of biologics for psoriasis"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1188-6707","authenticated-orcid":false,"given":"Nikki F T","family":"Henckens","sequence":"first","affiliation":[{"name":"Department of Dermatology, Radboud University Medical Centre (Radboudumc) , Nijmegen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0191-3293","authenticated-orcid":false,"given":"Marisol E","family":"Otero","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Radboud University Medical Centre (Radboudumc) , Nijmegen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-2673","authenticated-orcid":false,"given":"Juul M P A","family":"van den Reek","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Radboud University Medical Centre (Radboudumc) , Nijmegen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3872-5704","authenticated-orcid":false,"given":"Elke M G J","family":"de Jong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Radboud University Medical Centre (Radboudumc) , Nijmegen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the BioCAPTURE network","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romy R M C","family":"Keijsers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula P M","family":"van L\u00fcmig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge M","family":"Haeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith H J","family":"Hendricksen-Roelofzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E M","family":"K\u00f6rver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon R P","family":"Dodemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berit","family":"Velstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Femke M","family":"Homan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maartje A M","family":"Berends","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Jan","family":"Lindhout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annet M","family":"Oostveen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bas","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes M","family":"Mommers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martijn B A","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Tjioe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W Peter","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid L A","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marloes M","family":"Kleinpenning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"2025012715584428500_llae333-B1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/09546634.2017.1329501","article-title":"Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population","volume":"28","author":"Norris","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"2025012715584428500_llae333-B2","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3390\/jcm11061506","article-title":"Adherence and persistence to biological drugs for psoriasis: systematic review with meta-\u00adanalysis","volume":"11","author":"Piragine","year":"2022","journal-title":"J Clin Med"},{"key":"2025012715584428500_llae333-B3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2019.05.064","article-title":"Serial biologic therapies in psoriasis patients: a 12-year, single-center, retrospective observational study","volume":"82","author":"Cozzani","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025012715584428500_llae333-B4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s13555-022-00693-2","article-title":"Biologic therapy for moderate to severe psoriasis. Real-world follow-up of patients who initiated biologic therapy at least 10\u2005years ago","volume":"12","author":"Elberdin","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025012715584428500_llae333-B5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.17738","article-title":"Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis","volume":"181","author":"Mourad","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025012715584428500_llae333-B6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/bjd\/ljad280","article-title":"How to define a \u2018super-responder\u2019 to biologics in psoriasis studies","volume":"189","author":"Thomas","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025012715584428500_llae333-B7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/jdv.17829","article-title":"Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians","volume":"36","author":"van Ee","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae333\/60424033\/llae333.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/2\/348\/60424033\/llae333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/2\/348\/60424033\/llae333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T15:58:53Z","timestamp":1737993533000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/2\/348\/7733392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":7,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,8,14]]},"published-print":{"date-parts":[[2025,1,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae333","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,8,14]]}}}